Home / Business and Economy / AbbVie Surges on Strong Q3, Boosts Full-Year Profit Outlook
AbbVie Surges on Strong Q3, Boosts Full-Year Profit Outlook
30 Oct
Summary
- AbbVie's third-quarter revenue increased due to strong drug sales.
- The company's immunology and neuroscience drug sales were significant drivers.
- AbbVie raised its full-year adjusted earnings per share projection.
AbbVie experienced a notable increase in its third-quarter revenue, a performance bolstered significantly by strong sales from its immunology and neuroscience drug portfolios. This commercial success has prompted the company to raise its profit forecast for the entirety of the fiscal year.
As a result of the favorable third-quarter results, AbbVie now projects its full-year adjusted earnings per share to range between $13.95 and $13.99. This upward revision reflects the company's confidence in its ongoing business momentum and the sustained demand for its therapeutic offerings.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
